Description:
- Radiolabeled diagnostic tracer for PET imaging/scans
- Cancer and cardiovascular imaging
Abstract
- Radiolabeled diagnostic tracer for PET imaging/scans
- Cancer and cardiovascular imaging
Benefit
- Useful for in vivo imaging of tumor and organ tissues (e.g., heart, liver, brain, kidneys
- Direct ?uorination method of synthesis is convenient, produces sufficient amounts of activity, and is suitable for routine production for animal and human studies with PET
Market Application
Market Opportunity:
Positron emission tomography (PET) imaging is a non-invasive diagnostic tool that utilizes radiolabeled tracers to scan for organ function at the cellular level, unlike other diagnostic tools such as X-ray, CT, or MRI which predominantly look at structure. However, many tracers used for PET are rapidly catabolized before they are taken up by cells. Therefore, there is a demand for non-catabolized tracers.
USC Solution:
USC inventors have developed tracers that are 18F labeled adenosine analogs named [18F]FXA and [18F]FAA, which are more resistant to metabolization. Biodistribution studies and PET imaging of [18F]FXA in rodents suggest that these tracers maintained their effects 2 hours post-injection. Therefore, [18F]FXA is a promising lead compound for cardiac imaging whereas uptake of [18F]FAA was high in tumors, the spleen, and the liver and kidney. These novel [18F]-labeled analogs will be useful for PET imaging of organs and tumors.
Publications
Synthesis of [18F]-labeled adenosine analogues as potential PET imaging agents. J Label CompdRadiopharm. 2003.
Other
- Available for exclusive and non-exclusive license
- Status: Patent Issued, 8,506,926